Appointments to the National Cancer Register Board:

The Minister for Health, Jennifer Carroll MacNeill TD has appointed/re-appointed the following members to the National Cancer Registry Board:

Dr. Paul Kavanagh is a highly experienced medical doctor and public health specialist with over 15 years of expertise in leading national health projects and programs. He holds postgraduate qualifications in epidemiology, public health, and health data science and is a Fellow of the Faculty of Public Health Medicine in Ireland. Currently serving as a Consultant in Public Health Medicine at the HSE Health Intelligence Unit, Dr. Kavanagh leads innovative health data science initiatives, including predictive analytics and chronic disease data management. He has a strong background in cancer control, having conducted research on colorectal cancer epidemiology and provided leadership in tobacco control programs, both nationally and internationally. Dr. Kavanagh is an accomplished board member, contributing to strategic oversight at organisations such as the Institute of Public Health and various national committees. His work is grounded in evidence-based data and analytics, driving impactful decisions to improve healthcare and public health outcomes in Ireland.

Dr. Paul Kavanagh is appointed following a publicjobs campaign with effect from 8th July 2025 to 7 July 2029.

Mary Bourke is a graduate of University College Cork where she majored in Microbiology and completed a Master of Analytical Chemistry degree. She also completed a Diploma in Pharmaceutical Manufacturing Technology in Trinity College Dublin. She has worked in the pharmaceutical industry in Ireland, the United States, Puerto Rico, Spain and Switzerland. She has worked with GlaxoSmithKline, Schering Plough, Novartis, Wyeth, AbbVie, Pfizer and Bristol Myers Squibb. Her expertise is in the area of Quality Assurance and Quality Control in drug substance and drug product manufacture of both small and large molecules. She has established and led quality departments and is very knowledgeable in regulatory inspections by health authorities globally. She also led the Bristol Myers Squibb Global Risk Assessment programme for quality oversight of Contract Manufacturing Organizations. She has a unique breadth of experience through her leadership in quality assurance across organisations, geographies and regulatory authorities.

Ms Mary Bourke is reappointed with effect from 15 July 2025 to 14 July 2029.